

## Special Issue

# Precision Medicine in Hepatobiliary Cancer: Preclinical and Clinical Evidence

### Message from the Guest Editor

Primary liver cancer (PLC) is a frequent and deadly tumor worldwide. PLC consists mainly of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) in the adult, whereas hepatoblastoma (HB) is the prevalent hepatic malignancy in childhood.

In the last decade, as in many other tumor types, whole-genome sequencing studies together with a plethora of transcriptomic, proteomic, and metabolomic approaches have unraveled the molecular landscape of PLC. In addition, several in vitro and in vivo models have been generated to evaluate the possible vulnerability of tumors to innovative therapies. As a result, specific genetic and epigenetic events and peculiar metabolic features of the tumors have been identified. Effective and highly specific therapeutic approaches have been developed for some of them, and the concept of “precision medicine” (one patient = one treatment) has been established.

---

### Guest Editor

Prof. Dr. Diego F. Calvisi

Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany

---

### Deadline for manuscript submissions

closed (5 April 2022)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/97627](https://mdpi.com/si/97627)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).